Results 151 to 160 of about 126,024 (329)

PD‐1/PD‐L1 in Hepatocellular Carcinoma (2014–2024): A Combined Macro and Micro Analysis of Immunotherapy Implications

iNew Medicine, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu, Lin Tang, Hongyan Li, Hao Li, Jiamei Wang   +4 more
wiley   +1 more source

Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. [PDF]

, 2014
Activating mutations in FLT3 confer poor prognosis for individuals with acute myeloid leukemia (AML). Clinically active investigational FLT3 inhibitors can achieve complete remissions but their utility has been hampered by acquired resistance and ...
He, Bai-Liang, He, Bai-Liang, Lasater, Elisabeth A, Leung, Anskar Yh, Lin, Kimberly, Lopez, Michael S, Shah, Neil P, Shokat, Kevan M, Smith, Catherine C, Warkentin, Alexander A   +9 more
core  

Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling [PDF]

, 2012
M. Danielle Bareford, Hossein A. Hamed, Jeremy C. Allegood, Nichola Cruickshanks, Andrew Poklepovic, Margaret A. Park, Besim Öğretmen, Sarah Spiegel, Steven Grant, Paul Dent   +9 more
openalex   +1 more source

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source

Matrix stiffness regulates glucose-6-phosphate dehydrogenase expression to mediate sorafenib resistance in hepatocellular carcinoma through the ITGB1-PI3K/AKT pathway

Cell Death and Disease
Sorafenib is an antiangiogenic and antiproliferative chemotherapeutic drug that plays a crucial role in the treatment of patients with advanced hepatocellular carcinoma (HCC). However, resistance to sorafenib greatly limits its therapeutic efficacy. This
Ruimei Ren, Shan Zhang, Zhan Peng, Xiaomeng Ji, Hao Song, Qiuxiao Wang, Xiangyin Sun, Huiyu Wang, Yinying Dong   +8 more
doaj   +1 more source

Interaction of the Multikinase Inhibitors Sorafenib and Sunitinib with Solute Carriers and ATP-Binding Cassette Transporters [PDF]

, 2009
Shuiying Hu, Zhaoyuan Chen, Ryan M. Franke, Shelley Orwick, Ming Zhao, Michelle A. Rudek, Alex Sparreboom, Sharyn D. Baker   +7 more
openalex   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, EarlyView.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Peri‐implant hypoxia as a potential barrier against ferroptotic mechanisms during peri‐implant diseases: A cross‐sectional study

Journal of Periodontology, EarlyView.
Abstract Background Hypoxia modulates inflammation and oxidative stress through hypoxia‐inducible factor‐1α (HIF‐1α). Ferroptosis, an iron‐dependent cell death process, is regulated by glutathione peroxidase‐4 (GPX4) and involves lipid peroxidation markers like malondialdehyde (MDA).
Büşra Yılmaz, Ali Gürkan, Beral Afacan, Harika Atmaca, Timur Köse, Gülnur Emingil   +5 more
wiley   +1 more source

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin, Ming‐Lun Yeh, Po‐Cheng Liang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang   +8 more
wiley   +1 more source

The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]

, 2020
Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J, Kato, Shumei, Kurzrock, Razelle, Lippman, Scott M   +3 more
core